TY - JOUR

T1 - Development of a core outcome set for disease modification trials in mild to moderate dementia

T2 - a systematic review, patient and public consultation and consensus recommendations

AU - Webster, Lucy

AU - Groskreutz, Derek

AU - Grinbergs-Saull, Anna

AU - Howard, Rob

AU - O'Brien, John T.

AU - Mountain, Gail

AU - Banerjee, Sube

AU - Woods, Robert

AU - Perneczky, Robert

AU - Lafortune, Louise

AU - Roberts, Charlotte

AU - McCleery, Jenny

AU - Pickett, James

AU - Bunn, Frances

AU - Challis, David

AU - Charlesworth, Georgina

AU - Featherstone, Katie

AU - Fox, Chris

AU - Goodman, Claire

AU - Jones, Roy

AU - Lamb, Sallie

AU - Moniz-Cook, Esme

AU - Schneider, Justine

AU - Sheppard, Sasha

AU - Surr, Claire

AU - Thompson-Coon, Jo

AU - Ballard, Clive

AU - Brayne, Carol

AU - Burke, Orlaith

AU - Burns, Alistair

AU - Clare, Linda

AU - Garrard, Peter

AU - Kehoe, Patrick

AU - Passmore, Peter

AU - Holmes, Clive

AU - Maidment, Ian

AU - Murtagh, Fliss

AU - Robinson, Louise

AU - Livingston, Gill

N1 - © Queen’s Printer and Controller of HMSO 2017. This work was produced by Webster et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

PY - 2017/5

Y1 - 2017/5

N2 - In the UK, around 850,000 people have dementia. If a treatment can change the underlying pathology of dementia this is called disease modification, although no trials have yet found effective disease-modifying treatments. Trials have used differing outcome measures to evaluate if a treatment works, making it difficult to compare and contrast results. To address this issue we aimed, in collaboration with the UK dementia research community and the Alzheimer’s Society’s Research Network, to develop a core set of outcome measures for use in future disease-modifying trials for mild to moderate dementia.We looked at the outcomes used across completed and ongoing disease modification trials and found measures in six test areas: cognition, biological, behaviour, quality of life, activities of daily living and global. We used these findings to conduct a small consultation with people living with dementia and family carers. We presented all results at our consensus conference and discussed them to reach our conclusions.We recommend that the core set of outcome measures should include a cognitive measure, namely the Mini Mental State Examination or the Alzheimer’s Disease Assessment Scale – Cognitive subscale, and an optional magnetic resonance imaging scan looking at brain structure as a biological measure. We have specified measures for the other areas that are important but not core. The recommendations may change as new measures are developed, and, as most of the trials included participants with Alzheimer’s disease only, recommendations need to be developed for different dementias. They apply only to mild to moderate stages of dementia.

AB - In the UK, around 850,000 people have dementia. If a treatment can change the underlying pathology of dementia this is called disease modification, although no trials have yet found effective disease-modifying treatments. Trials have used differing outcome measures to evaluate if a treatment works, making it difficult to compare and contrast results. To address this issue we aimed, in collaboration with the UK dementia research community and the Alzheimer’s Society’s Research Network, to develop a core set of outcome measures for use in future disease-modifying trials for mild to moderate dementia.We looked at the outcomes used across completed and ongoing disease modification trials and found measures in six test areas: cognition, biological, behaviour, quality of life, activities of daily living and global. We used these findings to conduct a small consultation with people living with dementia and family carers. We presented all results at our consensus conference and discussed them to reach our conclusions.We recommend that the core set of outcome measures should include a cognitive measure, namely the Mini Mental State Examination or the Alzheimer’s Disease Assessment Scale – Cognitive subscale, and an optional magnetic resonance imaging scan looking at brain structure as a biological measure. We have specified measures for the other areas that are important but not core. The recommendations may change as new measures are developed, and, as most of the trials included participants with Alzheimer’s disease only, recommendations need to be developed for different dementias. They apply only to mild to moderate stages of dementia.

U2 - 10.3310/hta21260

DO - 10.3310/hta21260

M3 - Article

VL - 21

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 26

ER -